Serum levels of resistin and hsCRP in women with PCOS

[1] Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83:3078–3082. http://dx.doi.org/10.1210/jc.83.9.307810.1210/jc.83.9.3078Search in Google Scholar

[2] Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745–2749. http://dx.doi.org/10.1210/jc.2003-03204610.1210/jc.2003-032046Search in Google Scholar

[3] Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774–800. http://dx.doi.org/10.1210/er.18.6.77410.1210/er.18.6.774Search in Google Scholar

[4] Hopkinson ZE, Sattar N, Fleming R, Greer IA. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J 1998;317:329–332. 10.1136/bmj.317.7154.329Search in Google Scholar

[5] Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48–53. http://dx.doi.org/10.1210/jc.2005-132910.1210/jc.2005-1329Search in Google Scholar

[6] Steppan CM, Brown EJ, Wright CM Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98:502–506. http://dx.doi.org/10.1073/pnas.98.2.50210.1073/pnas.98.2.502Search in Google Scholar

[7] Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 409; 2001: 307–312. http://dx.doi.org/10.1038/3505300010.1038/35053000Search in Google Scholar

[8] Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472–476. http://dx.doi.org/10.1016/S0006-291X(02)02841-310.1016/S0006-291X(02)02841-3Search in Google Scholar

[9] Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50:2199–2202. http://dx.doi.org/10.2337/diabetes.50.10.219910.2337/diabetes.50.10.2199Search in Google Scholar PubMed

[10] Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285:561–564. http://dx.doi.org/10.1006/bbrc.2001.517310.1006/bbrc.2001.5173Search in Google Scholar PubMed

[11] Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 2002;530:158–162. http://dx.doi.org/10.1016/S0014-5793(02)03450-610.1016/S0014-5793(02)03450-6Search in Google Scholar

[12] Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309:286–290. http://dx.doi.org/10.1016/j.bbrc.2003.07.00310.1016/j.bbrc.2003.07.003Search in Google Scholar

[13] Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Gosh S, Ehtesham NZ, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005; 334:1092–1101. http://dx.doi.org/10.1016/j.bbrc.2005.06.20210.1016/j.bbrc.2005.06.202Search in Google Scholar

[14] Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1:45–52. http://dx.doi.org/10.1371/journal.pmed.001004510.1371/journal.pmed.0010045Search in Google Scholar

[15] Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 2005; 105: 409–416. Search in Google Scholar

[16] Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein. Curr Probl Cardiol 2004; 29:439–493. 10.1016/j.cpcardiol.2004.03.004Search in Google Scholar

[17] Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–843. http://dx.doi.org/10.1056/NEJM20000323342120210.1056/NEJM200003233421202Search in Google Scholar

[18] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004; 19: 41–47. http://dx.doi.org/10.1093/humrep/deh09810.1093/humrep/deh098Search in Google Scholar

[19] Ukkola O. Resistin: a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002; 147: 571–574. http://dx.doi.org/10.1530/eje.0.147057110.1530/eje.0.1470571Search in Google Scholar

[20] Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metabol 2002; 13: 18–22. http://dx.doi.org/10.1016/S1043-2760(01)00522-710.1016/S1043-2760(01)00522-7Search in Google Scholar

[21] Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 361–365. http://dx.doi.org/10.1016/j.fertnstert.2003.06.02110.1016/j.fertnstert.2003.06.021Search in Google Scholar PubMed

[22] Kelly CC, lyall H, Petrie JR, Gould GW, Connell JM, Satar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453–2455. http://dx.doi.org/10.1210/jc.86.6.245310.1210/jc.86.6.2453Search in Google Scholar

[23] Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592–5596. http://dx.doi.org/10.1210/jc.2004-075110.1210/jc.2004-0751Search in Google Scholar PubMed

[24] Bickerton AS, Clarck N, Meeking D, Shaw KM, Crook M, Lumb P, Turner C and Cummings MH. Cardiovascular risk in women with polycystic ovarian syndrome. J Clin Pathol 2005; 58: 151–154. http://dx.doi.org/10.1136/jcp.2003.01527110.1136/jcp.2003.015271Search in Google Scholar PubMed PubMed Central

[25] Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G and Schofl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150:525–532. http://dx.doi.org/10.1530/eje.0.150052510.1530/eje.0.1500525Search in Google Scholar PubMed

[26] Hu WL, Qian SB, Li JL. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Cytokine 2007; 40:201–206. http://dx.doi.org/10.1016/j.cyto.2007.09.01110.1016/j.cyto.2007.09.011Search in Google Scholar PubMed

[27] Rittmaster RS, Deshwal N, Lehman L. The role of adrenal hyperandrogenism, insulin resistance and obesity in the pathogenesis of polycystic ovarian syndrome. J Clin Endocrinol Metab 1993; 76:1295–1300. http://dx.doi.org/10.1210/jc.76.5.129510.1210/jc.76.5.1295Search in Google Scholar

[28] Polderman KH, Gooren JG, Asscherman H, Bakker A and Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994; 79: 265–271. http://dx.doi.org/10.1210/jc.79.1.26510.1210/jc.79.1.265Search in Google Scholar

[29] Seow KM, Juan CH, Wu LY, Hsu YP, Yang WM, Tsai YL, Hwang JL and Ho LT. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod 2004;19: 48–53. http://dx.doi.org/10.1093/humrep/deh01010.1093/humrep/deh010Search in Google Scholar PubMed